drugset / Trial / NCT04018261
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Phase 1/2
Completed
26 enrolled
Blood and Tissue Bank of Catalonia
Hospital Universitario La Fe · collabVall d'Hebron Institute of Oncology · collab
NaSingle-groupOpen-labelTreatment
Summary
Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor. Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days after the treatment.
Timeline
- Start
- 2019-07-04
- Primary completion
- 2021-10-18
- Completion
- 2021-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Activated T-Lymphocytes | Unknown | 100 cells/kg | Intravenous |
| Subject | Activated T-Lymphocytes | Unknown | 50000 cells/kg | Intravenous |